Chemerix Biotech Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 21-06-2024
- Paid Up Capital ₹ 5.00 M
as on 21-06-2024
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 20.70 M
as on 21-06-2024
- Revenue 189.55%
(FY 2022)
- Profit 173.62%
(FY 2022)
- Ebitda 336.50%
(FY 2022)
- Net Worth 33.42%
(FY 2022)
- Total Assets -26.13%
(FY 2022)
About Chemerix Biotech
The Corporate was formerly known as Camus Biotech Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company has closed loans amounting to ₹2.07 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Kaushalya Punia, Amod Mishra, and Ravi Verma serve as directors at the Company.
- CIN/LLPIN
U24304RJ2017PTC058071
- Company No.
058071
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 May 2017
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Chemerix Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kaushalya Punia  | Director | 26-Aug-2019 | Current |
| Amod Mishra | Director | 30-Mar-2018 | Current |
| Ravi Verma | Director | 19-May-2017 | Current |
Financial Performance and Corporate Structure Insights of Chemerix Biotech.
Chemerix Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 189.55% increase. The company also saw a substantial improvement in profitability, with a 173.62% increase in profit. The company's net worth Soared by an impressive increase of 33.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chemerix Biotech?
In 2021, Chemerix Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Iatric Lifescience Private Limited
Active 7 years 4 monthsAmod Mishra and Ravi Verma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Dec 2017 | ₹2.07 Cr | Satisfied |
How Many Employees Work at Chemerix Biotech?
Chemerix Biotech has a workforce of 27 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chemerix Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chemerix Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
